Begin typing your search above and press return to search.
Amid India-Canada diplomatic row
access_time 22 Sep 2023 4:00 AM GMT
K Radhakrishnan
access_time 21 Sep 2023 4:00 AM GMT
Womens quota in legislatures
access_time 20 Sep 2023 5:24 AM GMT
Extended Congress CWC meet raises hopes
access_time 19 Sep 2023 5:11 AM GMT
The saboteurs in the market of hate
access_time 18 Sep 2023 9:47 AM GMT
CAG report amidst Keralas financial crisis
access_time 16 Sep 2023 4:28 AM GMT
Schools breeding hatred
access_time 14 Sep 2023 10:37 AM GMT
access_time 16 Aug 2023 5:46 AM GMT
Remembering the Teachers
access_time 5 Sep 2023 6:24 AM GMT

Omicron-specific vaccine in 6 months: SII CEO Poonawalla

Omicron-specific vaccine in 6 months: SII CEO Poonawalla

Serum Institute of India CEO Adar Poonawalla

New Delhi: The CEO of Serum Institute of India (SII), Adar Poonawalla, said on Thursday that SII will launch an Omicron-specific vaccine for COVID-19 six months from now, PTI reported.

He informed that there is good data available on the Covovax vaccine.

He said, "The original Novovax vaccine Covovax covers omicron, and there is good data for it. We will try to launch an Omicron-specific vaccine after six months."

The SII, based in Pune, is working with the US biotechnology giant Novavax to develop the Omicron-specific vaccine.

The World Health Organisation has declared the Omicron sub-variant of COVID-19 as a variant of concern after its speedy transmission.

SII's Covavax vaccine is available for those above the age of 12 in India.

On monkeypox, Mr Poonawalla said the need for a vaccine is "debatable".

"Yes, it created a little bit of buzz when we saw the cases here. We are conducting research on the topic and can collaborate with the Department of Biotechnology on it too. Our research is going on, and we will see in six months," he said.

Show Full Article
TAGS:Covid-19OmicronvaccineSIIAdar Poonawallamonkeypox
Next Story